Please confirm you are human (Sign Up for free to never see this)
← Back to Search
The Emerging Role Of The Insulin-like Growth Factor Pathway As A Therapeutic Target In Cancer.
P. Ryan, P. Goss
Published 2008 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The insulin-like growth factor signaling pathway is important in many human cancers based on data from experimental models as well as epidemiological studies. Important therapies targeted at this pathway have been or are being developed, including monoclonal antibodies to the insulin-like growth factor-I receptor and small molecule inhibitors of the tyrosine kinase function of this receptor. These investigational therapies are now being studied in clinical trials. Emerging data from phase I trials are encouraging regarding the safety of the monoclonal antibodies. In this manuscript, the rationale for targeting the insulin-like growth factor system is reviewed in addition to a summary of the available clinical trial data.
This paper references
Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort.
I. Cheng (2006)
Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells.
L. R. Wiseman (1993)
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
June M. Chan (1998)
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody
Yan Wang (2005)
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
F. Morgillo (2006)
Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.
M. Cardillo (2003)
Involvement of insulin-like growth factor-I in the control of glucose homeostasis.
D. Clemmons (2006)
Sex hormone‐induced prostatic carcinogenesis in the Noble rat: The role of insulin‐like growth factor‐1 (IGF‐1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer
Y. Wang (1998)
Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus.
P. Pennisi (2006)
CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia.
N. Tsuchiya (2005)
The role of the IGF system in cancer growth and metastasis: overview and recent insights.
A. Samani (2007)
Recombinant Human Insulin-Like Growth Factor I Increases Insulin Sensitivity and Improves Glycemic Control in Type II Diabetes
A. Moses (1996)
Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling.
K. Kalli (2002)
Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis.
C. Shimizu (2004)
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.
C. García-Echeverría (2004)
Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model.
T. Habuchi (2006)
Distinct and overlapping functions of insulin and IGF-I receptors.
J. Nakae (2001)
Variation among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses.
T. Petley (1999)
Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871
B. D. Cohen (2005)
IGF-I mediated survival pathways in normal and malignant cells.
R. Kurmasheva (2006)
The IGF‐1 receptor in cancer biology
R. Baserga (2003)
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
J. Gee (2005)
The Insulin-like Growth Factor 1 Receptor Induces Physiological Heart Growth via the Phosphoinositide 3-Kinase(p110α) Pathway*
J. McMullen (2004)
Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development.
W. Ruan (1999)
Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors
P. Haluska (2007)
Polymorphisms in the IGF-1 and IGFBP3 promoter and the risk of breast cancer
K. Wagner (2005)
Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer.
Y. Chang (2002)
A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer
J. Rodon (2007)
The insulin and insulin-like growth factor-I receptor substrate IRS-1 associates with and activates phosphatidylinositol 3-kinase in vitro.
S. Giorgetti (1993)
Promoter −202 A/C polymorphism of insulin‐like growth factor binding protein‐3 gene and non‐small cell lung cancer risk
Jin Wook Moon (2006)
Cellular actions of the insulin-like growth factor binding proteins.
S. Firth (2002)
The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane
R. X. Song (2004)
Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
J. Knowlden (2005)
A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors
C. Higano (2007)
Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity
D. Yin (2005)
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.
J. Carboni (2005)
Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
A. Camirand (2002)
Growth Inhibition of Human Prostate Cancer Cells in Human Adult Bone Implanted into Nonobese Diabetic/Severe Combined Immunodeficient Mice by a Ligand-Specific Antibody to Human Insulin-Like Growth Factors
M. Goya (2004)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
C. Mitsiades (2004)
Polymorphic CA repeats in the IGF-I gene and breast cancer
H. Yu (2004)
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
D. Burtrum (2003)
Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas.
Abderrahman Ouban (2003)
Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults.
H. Guler (1987)
The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients.
M. Railo (1994)
In vivo metabolic action of insulin-like growth factor I in adult rats
F. Schmitz (2004)
Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC)
D. Karp (2007)
Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer.
N. Tsuchiya (2006)
Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology.
A. Butler (1998)
Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene.
K. Woods (1996)
Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway.
X. Wan (2002)
Impact of IGF‐1R/EGFR cross‐talks on hepatoma cell sensitivity to gefitinib
C. Desbois-Mouthon (2006)
Role of insulin-like growth factor binding proteins in controlling IGF actions
D. Clemmons (1998)
Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
I. McCutcheon (2001)
Insulin-like growth factors and neoplasia
M. Pollak (2004)
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers
M. Letsch (2003)
IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation.
M. Abuzzahab (2003)
Insulin-like Growth Factors Regulate Neuronal Differentiation and Survival
E. Feldman (1997)
IGF1 gene polymorphism and risk for hereditary nonpolyposis colorectal cancer.
Maja Zečević (2006)
Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.
H. Yu (1999)
Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice.
J. DiGiovanni (2000)
The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.
H. Khandwala (2000)
The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis.
A. Samani (2001)
Structural biology of insulin and IGF1 receptors: implications for drug design
P. D. Meyts (2002)
Insulin-like growth factor-I receptors and estrogen receptors interact in the promotion of neuronal survival and neuroprotection
L. García-segura (2000)
Human insulin-like growth factor-IA expression in transgenic mice promotes adenomatous hyperplasia but not pulmonary fibrosis.
S. Frankel (2005)
Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis
D. Hadsell (2000)
A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
A. W. Tolcher (2007)
Mechanisms of Disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer
Y. Tao (2007)
Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation.
E. Surmacz (1995)
Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3
A. Renehan (1999)
An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
E. Maloney (2003)
A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
D. Sachdev (2003)
Growth hormone / insulin-like growth factor-1 axis during puberty.
Athanasios Christoforidis (2005)
Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
Y. Chang (2002)
Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia.
S. Abe (2006)
Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype.
Y. Xie (1999)
Pre-clinical evaluation of the anti-tumor activity of the IGF1R - specific anitbody AVE1642
F. Bladt (2006)
A recombinant humanized anti‐insulin‐like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti‐epidermal growth factor receptor therapy against human cancer xenografts
L. Goetsch (2005)
Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation.
U. Hermanto (2000)
Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice.
C. van den Berg (1997)
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
P. Haluska (2006)
The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge
R. Durai (2004)
Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer
Y. Chang (2004)
Effects of growth hormone on glucose metabolism.
N. Møller (1991)
Insulin-like growth factors and their binding proteins: biological actions.
J. I. Jones (1995)
Insulin-like growth factor-I receptor signaling blockade combined with radiation.
G. W. Allen (2007)
Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells.
A. Grey (2003)
Intact and amino-terminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development.
W. Ruan (1992)
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
S. Hankinson (1998)
This paper is referenced by
Monoclonal antibodies in oncology therapeutics: present and future indications
D. Bhutani (2013)
Differential PKA activation and AKAP association determines cell fate in cancer cells
Erik Hedrick (2013)
Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
T. Okusaka (2014)
SHORT REPORT Insulin-like growth factor 1 receptor expression in wild-type GISTs: A potential novel therapeutic target
M. Pantaleo (2009)
Igf1r as a therapeutic target in a mouse model of basal-like breast cancer
A. Klinakis (2009)
Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations
D. Olmos (2011)
Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier
R. Sangha (2009)
Role of anabolic agents in colorectal carcinogenesis: Myths and realities
Theodore Krasanakis (2019)
β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma.
C. Xu (2013)
Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression
Cai Qun Bie (2016)
Chromogranin A regulates neuroblastoma proliferation and phenotype
D. Zhang (2019)
Molecular markers in epithelial ovarian cancer: paving the way to innovative therapies
P. D. Graeff (2009)
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors
Haruyasu MurakamiToshihiko (2012)
Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.
John L. Buchanan (2011)
Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro
V. D'esposito (2012)
Downregulation of IGF1R Expression Inhibits Growth and Enhances Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cells In Vitro
A. Khalil (2018)
Effects of insulin-like growth factor-1 on B-cell precursor acute lymphoblastic leukemia
H. Yamada (2012)
Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review.
M. Yin (2009)
Signal transduction therapy of cancer.
A. Levitzki (2010)
Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo — challenges and prospects
Judith Jakoby (2015)
Circadian aspects of growth hormone-insulin-like growth factor axis function in patients with lung cancer.
G. Mazzoccoli (2012)
Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.
Jennifer H. Law (2008)
MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas
H. Zhong (2014)
An Insulin-Like Growth Factor 1 Receptor Inhibitor Induces CYP3A4 Expression through a Pregnane X Receptor-Independent, Noncanonical Constitutive Androstane Receptor-Related Mechanism
L. Li (2012)
Ligand-Specific Antibodies to Insulin-Like Growth Factors Suppress Intestinal Polyp Formation in Apc+/− Mice
T. Matsunaka (2010)
[Research progress on the relationship between insulin-like growth factor-I and lung cancer].
Zhe Liu (2010)
Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours
H. Iguchi (2014)
Anthocyanins in Vascular Diseases
A. Speciale (2014)
Estrogen upregulates the IGF-1 signaling pathway in lung cancer through estrogen receptor-β
Hexiao Tang (2012)
The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors
M. Belinsky (2008)
Down-regulation of IGF-1R expression inhibits growth and enhances chemosensitivity of endometrial carcinoma in vitro
Shanrong Shu (2011)
Histomorphometric features of ventral prostate in different aged rats after central ghrelin treatment.
B. Plećaš-Solarović (2012)See more